Safety of bisphosphonates

Bone

Volumn 49, Issue 1, 2011, Pages 103-110

  Pazianas, Michael ^a   Abrahamsen, Bo ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Atrial fibrillation; Bisphosphonates; Cancer; ONJ; Subtrochanteric fractures

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE PLUS RISEDRONIC ACID; DENOSUMAB; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ARTHRALGIA; BONE METASTASIS; BONE PAIN; CHILL; CONJUNCTIVITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DUODENITIS; DYSPEPSIA; EPISCLERITIS; EROSION; ESOPHAGEAL IRRITATION; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS DISEASE; ESOPHAGUS EROSION; FEMUR FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FLU LIKE SYNDROME; FRAGILITY FRACTURE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL EROSION; GASTROINTESTINAL IRRITATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEARTBURN; HUMAN; IRITIS; JAW OSTEONECROSIS; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; SCLERITIS; STOMACH EROSION; STOMACH IRRITATION; UVEITIS;

DIPHOSPHONATES; DISEASE; GASTROINTESTINAL TRACT; HUMANS;

EID: 79958732151     PISSN: 87563282     EISSN: 87563282     Source Type: Journal    
DOI: 10.1016/j.bone.2011.01.003     Document Type: Review

References (97)

1. Biswas P.N., Wilton L.V., Shakir S.A. Pharmacovigilance study of alendronate in England. Osteoporos Int 2003, 14:507-514.
2. Graham D.Y. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002, 47:1665-1678.
3. Peter C.P., Handt L.K., Smith S.M. Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci 1998, 43:1998-2002.
4. Reszka A.A., Halasy-Nagy J., Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001, 59:193-202.
5. Lichtenberger L.M., Romero J.J., Gibson G.W., Blank M.A. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 2000, 45:1792-1801.
6. Cadarette S.M., Katz J.N., Brookhart M.A., Sturmer T., Stedman M.R., Levin R., et al. Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int 2009, 20(10):1735-1747.
7. Thomson A.B., Marshall J.K., Hunt R.H., Provenza J.M., Lanza F.L., Royer M.G., et al. 14day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 2002, 29:1965-1974.
8. Lanza F.L., Hunt R.H., Thomson A.B., Provenza J.M., Blank M.A. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000, 119:631-638.
9. Lanza F., Sahba B., Schwartz H., Winograd S., Torosis J., Quan H., et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002, 97:58-64.
10. Rosen C.J., Hochberg M.C., Bonnick S.L., McClung M., Miller P., Broy S., et al. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005, 20:141-151.
11. Wysowski D.K. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:89-90.
12. Cardwell C.R., Abnet C.C., Cantwell M.M., Murray L.J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010, 304:657-663.
13. Green J., Czanner G., Reeves G., Watson J., Wise L., Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010, 341:c4444.
14. Abrahamsen B., Eiken P., Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:1789-1792.
15. Solomon D.H., Patrick A., Brookhart M.A. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:1789-1790.
16. Burr D.B., Turner C.H., Naick P., Forwood M.R., Ambrosius W., Hasan M.S., et al. Does microdamage accumulation affect the mechanical properties of bone?. J Biomech 1998, 31:337-345.
17. Akkus O., Polyakova-Akkus A., Adar F., Schaffler M.B. Aging of microstructural compartments in human compact bone. J Bone Miner Res 2003, 18:1012-1019.
18. Wasserman N., Yerramshetty J., Akkus O. Microcracks colocalize within highly mineralized regions of cortical bone tissue. Eur J Morphol 2005, 42:43-51.
19. Leeming D.J., Henriksen K., Byrjalsen I., Qvist P., Madsen S.H., Garnero P., Karsdal M.A. Is bone quality associated with collagen age?. Osteoporos Int 2009 Sep, 20(9):1461-1470.
20. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100:1475-1480.
21. Meunier P.J., Arlot M., Chavassieux P., Yates A.J. The effects of alendronate on bone turnover and bone quality. Int J Clin Pract Suppl 1999, 101:14-17.
22. Peter C.P., Cook W.O., Nunamaker D.M., Provost M.T., Seedor J.G., Rodan G.A. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 1996, 14:74-79.
23. Ing-Lorenzini K., Desmeules J., Plachta O., Suva D., Dayer P., Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009, 32:775-785.
24. Kwek E.B., Goh S.K., Koh J.S., Png M.A., Howe T.S. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39:224-231.
25. Lenart B.A., Lorich D.G., Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008, 358:1304-1306.
26. Visekruna M., Wilson D., McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008, 93:2948-2952.
27. Lee J.K. Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium. Int J Rheum Dis 2009, 12:149-154.
28. Schilcher J., Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009, 80:413-415.
29. Aspenberg P., Schilcher J., Fahlgren A. Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack. Acta Orthop 2010, 81:460-462.
30. Cermak K., Shumelinsky F., Alexiou J., Gebhart M.J. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res 2010, 468:1991-1996.
31. Koh J.S., Goh S.K., Png M.A., Kwek E.B., Howe T.S. Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?. J Orthop Trauma 2010, 24:75-81.
32. Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20(8):1353-1362.
33. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., Lorich D.G. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22:346-350.
34. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
35. Odvina C.V., Levy S., Rao S., Zerwekh J.E., Sudhaker R.D. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010, 72(2):161-168.
36. Armamento-Villareal R., Napoli N., Panwar V., Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006, 355:2048-2050.
37. Armamento-Villareal R., Napoli N., Diemer K., Watkins M., Civitelli R., Teitelbaum S., et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009, 85:37-44.
38. Somford M.P., Draijer F.W., Thomassen B.J., Chavassieux P.M., Boivin G., Papapoulos S.E. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009, 24(10):1736-1740. PubMed PMID: 19419297.
39. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25(11):2267-2294.
40. Dell R., Greene D., Ott S.M., Silverman S., Eisemon E., Funahashi T., et al. A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009. ASBMR 2010 Annual Meeting, Toronto, Canada. 2010 (Abstract) 2010.
41. Vestergaard P. Risk of femoral shaft and subtrochanteric fractures in users of bisphophonates, raloxifene and strontium ranelate 2010.
42. Abrahamsen B., Eiken P., Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010, 95(12):5258-5265.
43. Nieves J.W., Bilezikian J.P., Lane J.M., Einhorn T.A., Wang Y., Steinbuch M., et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010, 21(3):399-408.
44. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010, 86:421-435.
45. Watts N.B., Diab D.L. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010, 95:1555-1565.
46. Editor's note: phosphorus necrosis under control. B Dent J 1944, 76:343.
47. Ruggiero S.L., Mehrotra B., Rosenberg T.J., Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62:527-534.
48. Coleman R.E., Woodward E.J., Brown J.E., Cameron D., Bell R., Dodwell D., Keane M., Gil M., Davies C., Burkinshaw R., Houston S.J., Grieve R.J., Barrett-Lee P.J., Thorpe H. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomized phase III trial for women with stage II/III breast cancer 2010.
49. Brown J.E., Barrios C.H., Diel I.J., Facon T., Fizazi K., Ibrahim T., Saad F., Senecal F., Stemmer S.M., Stopeck A., Takahashi S., Van Poznak C., Zhou L., Carriere P., Daniels A., Dansey R. Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma 2010.
50. Pazianas M., Miller P., Blumentals W.A., Bernal M., Kothawala P. Prevalence, risk factors and clinical characteristics of osteonecrosis of the Jaw (ONJ) in osteoporosis patients treated with bisphosphonates. Clin Ther 2007, 29:1548-1558.
51. Lo J.C., O'Ryan F.S., Gordon N.P., Yang J., Hui R.L., Martin D., Hutchinson M., Lathon P.V., Sanchez G., Silver P., Chandra M., McCloskey C.A., Staffa J.A., Willy M., Selby J.V., Go A.S. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010, 68(2):243-253.
52. Bertoldo F., Santini D., Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 2007, 4:711-721.
53. Wimalawansa S.J. Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf 2008, 7(4):491-512.
54. Wilkinson G.S., Kuo Y.F., Freeman J.L., Goodwin J.S. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007, 99(13):1016-1024.
55. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 2011, 103:1-9.
56. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491. American Society for Bone and Mineral Research.
57. Ruggiero S.L., Dodson T.B., Assael L.A., Landesberg R., Marx R.E. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009, 67(5 Suppl):2-12. American Association of Oral and Maxillofacial Surgeons.
58. Van Poznak C. Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat 2010, 122(1):189-191.
59. Guarneri V., Miles D., Robert N., et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010, 122(1):181-188.
60. Estilo C.L., Van Poznak C.H., Wiliams T., et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008, 13(8):911-920.
61. Aragon-Ching J.B., Ning Y.M., Chen C.C., et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Investig 2009, 27:221-226.
62. Khosla S., Burr D., Cauley J., et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2008, 66:1320-1321. American Society for Bone and Mineral Research Task Force on Osteonecrosis of the Jaw.
63. Novince C.M., Ward B.B., McCauley L.K. Osteonecrosis of the jaw: an update and review of recommendations. Cells Tissues Organs 2009, 189:275-283. Epub 2008 Sep 1.
64. Lehrer S., Montazem A., Ramanathan L., et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008, 106:389-391.
65. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., Mautalen C., Mesenbrink P., Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T.F., Sellmeyer D., Eriksen E.F., Cummings S.R. HORIZON Pivotal Fracture Trial Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
66. Lyles K.W., Colón-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., Hyldstrup L., Recknor C., Nordsletten L., Moore K.A., Lavecchia C., Zhang J., Mesenbrink P., Hodgson P.K., Abrams K., Orloff J.J., Horowitz Z., Eriksen E.F., Boonen S. HORIZON Recurrent Fracture Trial Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
67. Cummings S.R., Schwartz A.V., Black D.M. Alendronate and atrial fibrillation. N Engl J Med 2007, 356:1895-1896.
68. Karam R., Camm J., McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007, 357:712-713.
69. Lewiecki E.M., Cooper C., Thompson E., Hartl F., Mehta D., Papapoulos S.E. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract 2010, 64(6):821-826. Epub 2010 Mar 11.
70. Food and Drug Administration (FDA) Drug safety communications-volume 2, number 1, 2009 Available at:, Accessed August 28, 2010. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm118262.htm.
71. European Medicines Agency (EMEA) Aclasta (zoledronic acid): European public assessment report, revision 9. London: EMEA; Jul 8, 2009 Available from:, Accessed August 28, 2010. http://www.emea.europa.eu/humandocs/Humans/EPAR/aclasta/aclasta.htm.
72. Bisphosphonates and atrial fibrillation. Drug Safety Update 2008, 1(12):4. from MHRA and CHM.
73. Sørensen H.T., Christensen S., Mehnert F., Pedersen L., Chapurlat R.D., Cummings S.R., Baron J.A. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008, 336:813-816.
74. Abrahamsen B., Eiken P., Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 2009, 265:581-592.
75. Heckbert S.R., Li G., Cummings S.R., Smith N.L., Psaty B.M. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008, 168:826-831.
76. Michael Pazianas M., Cooper C.R., Wang Y., Lange L.J., Graham G., Russell R.G.G. Lack of association between of atrial fibrillation and the use of oral bisphosphonates. Osteoporos Int 2010, 21(Suppl1):S82.
77. Grosso A., Douglas I., Hingorani A., MacAllister R., Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS ONE 2009, 4(3):e4720.
78. Loke Y.K., Jeevanantham V., Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009, 32:219-228.
79. Bhuriya R., Singh M., Molnar J., Arora R., Khosla S. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2010, 142(3):213-217.
80. Pazianas M., Compston J., Huang C.L. Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res 2010, 25(1):2-10.
81. Olson K., Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract 2007, 13(4):223-229.
82. Adami S., Bhalla A.K., Dorizzi R., et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987, 41(6):326-331.
83. Frijlink W.B., Bijvoet O.L., te Velde J., Heynen G. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet 1979, 1(8120):799-803.
84. Reginster J.Y., Adami S., Lakatos P., et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2year results from the MOBILE study. Ann Rheum Dis 2006, 65:654-661.
85. Reid I.R., Gamble G.D., Mesenbrink P., Lakatos P., Black D.M. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 2010 Sep, 95(9):4380-4387.
86. Roelofs A.J., Jauhiainen M., Mönkkönen H., Rogers M.J., Mönkkönen J., Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2009, 144(2):245-250.
87. Macarol V., Fraunfelder F.T. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994, 118:220-224.
88. French D.D., Margo C.E. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina 2008, 28(6):889-893.
89. Fraunfelder F.W., Fraunfelder F.T., Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003, 135:219-222.
90. Asensio Sánchez V.M., Botella Oltra G., Carrasco E. Biphosphonates and intraocular inflammation. Arch Soc Esp Oftalmol 2004, 79:85-87.
91. Pouvreau I., Zech J.C., Thillaye-Goldenberg B., Naud M.C., Van Rooijen N., de Kozak Y. Effect of macrophage depletion by liposomes containing dichloromethylene-diphosphonate on endotoxin-induced uveitis. J Neuroimmunol 1998, 86(2):171-181.
92. Wysowski D.K., Chang J.T. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005, 165:346-347.
93. Bock O., Boerst H., Thomasius F.E., et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 2007, 7(2):144-148.
94. Severe pain with osteoporosis drugs. FDA patient safety news: show #73, March 2008 Accessed Dec 2, 2010. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/printer.cfm?id=746.
95. Reid D.M., Devogelaer J.P., Saag K., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373(9671):1253-1263.
96. Caplan L., Pittman C.B., Zeringue A.L., Scherrer J.F., Wehmeier K.R., Cunningham F.E., Eisen S.A., McDonald J.R. An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy. Mayo Clin Proc 2010 Apr, 85(4):341-348.
97. Morag Y., Morag-Hezroni M., Jamadar D.A., et al. Bisphosphonate-related osteonecrosis of the jaw: a pictorial review. Radiographics 2009, 29(7):1971-1984.